Supplement

You have full text access to this OnlineOpen article

Breast radiation therapy guideline implementation in low- and middle-income countries†

  1. Nuran Senel Bese MD1,‡,*,
  2. Anusheel Munshi MD2,
  3. Ashwini Budrukkar MBBS, DMRT, MD, DNB2,
  4. Ahmed Elzawawy MD3,4,
  5. Carlos A. Perez MD5,
  6. on behalf of the Breast Health Global Initiative Radiation Therapy Focus Group §

Article first published online: 3 OCT 2008

DOI: 10.1002/cncr.23838

Issue

Cancer

Cancer

Supplement: Guidelines for International Breast Health and Cancer Control–Implementation

Volume 113, Issue Supplement 8, pages 2305–2314, 15 October 2008

Additional Information

How to Cite

Bese, N. S., Munshi, A., Budrukkar, A., Elzawawy, A., Perez, C. A. and on behalf of the Breast Health Global Initiative Radiation Therapy Focus Group (2008), Breast radiation therapy guideline implementation in low- and middle-income countries. Cancer, 113: 2305–2314. doi: 10.1002/cncr.23838

Author Information

  1. 1

    Istanbul University, Cerrahpasa Medical School Department of Radiation Oncology, Cerrahpasa, Istanbul, Turkey

  2. 2

    Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India

  3. 3

    Faculty of Medicine, Suez Canal University, Suez, Egypt

  4. 4

    Al-Soliman Radiation Oncology Unit, Port Said Early Detection and Cancer Chemotherapy Unit, Port Said General Hospital, Insurance Hospitals, Port Said, Egypt

  5. 5

    Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri

  1. ‡

    Fax: (011) 90-212 414 31 01

  2. §

    The Radiation Therapy Focus Group: Baffour Awuah, Nuran Senel Bese, Ashwini Budrukkar, Robert W. Carlson, Ahmed Elzawawy, Alexandru Eniu, Anusheel Munshi, and Carlos Perez.

*Radiation Oncology, Istanbul University, Cerrahpasa Medical School Department of Radiation Oncology, Cerrahpasa, 34098 Istanbul, Turkey

  1. †

    Complete financial disclosures are presented at the end of this article.

Publication History

  1. Issue published online: 3 OCT 2008
  2. Article first published online: 3 OCT 2008
  3. Manuscript Accepted: 24 JUN 2008
  4. Manuscript Received: 10 JUN 2008

Funded by

  • The Breast Health Global Initiative Global Summit
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Ethicon Endo Surgery, Inc.
  • GE Healthcare
  • F. Hoffmann-La Roche AG
  • Novartis Oncology
  • Pfizer Inc.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (123K)

REFERENCES

  • 1
    Whelan T,Darby S,Taylor C,McGale P,Ewertz M. Overviews of Randomized Trials of Radiotherapy in Early Breast Cancer. 2007 Educational Book. Alexandria, Va: American Society of Clinical Oncology; 2007: 3–6.
  • 2
    Danish Breast Cancer Cooperative Group, Nielsen HM,Overgaard M,Grau C,Jensen AR,Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol. 2006; 24: 2268–2275.
  • 3
    Ragaz J,Olivotto IA,Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005; 97: 116–126.
  • 4
    El Saghir NS,Khalil MK,Eid T, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007; 5: 225–233.
  • 5
    Agarwal G,Pradeep PV,Aggarwal V,Yip CH,Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007; 31: 1031–1040.
  • 6
    Levin CV,El Gueddari B,Meghzifene A. Radiation therapy in Africa: distribution and equipment. Radiother Oncol. 1999; 52: 79–84.
  • 7
    Tatsuzaki H,Levin CV. Quantative status of resources for radiation therapy in Asia and Pacific region. Radiother Oncol. 2001; 60: 81–89.
  • 8
    Zubizarreta EH,Poitevin A,Levin CV. Overview of radiotherapy resources in Latin America: a survey by the International Atomic Energy Agency (IAEA). Radiother Oncol. 2004; 73: 97–100.
  • 9
    Bese N,Kiel K,El-Guaddari B-K,Campbell OB,Awuah B,Vikram B;International Atomic Energy Agency. Radiotherapy for breast cancer in countries with limited resources: program implementation and evidence-based recommendations. Breast J. 2006; 12( suppl. 1): S96–S102.
    Direct Link:
  • 10
    International Atomic Energy Agency (IAEA). Design and Implementation of a Radiotherapy Programme: Clinical, Medical Physics, Radiation Protection and Safety Aspects. IAEA TECDOC-1040. Vienna, Austria: IAEA; 2005.
  • 11
    Barton MB,Frommer M,Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol. 2006; 7: 584–595.
  • 12
    Van Der Giessen PH,Alert J,Badri C, et al. Multinational assessment of some operational costs of teletherapy. Radiother Oncol. 2004; 71: 347–355.
  • 13
    Bese NS,Sut PA,Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. Oncology. 2005; 69: 214–223.
  • 14
    Eniu A,Carlson RW,El Saghir NS, et al. Breast Health Global Initiative guidelines implementation in low- and middle-income countries: treatment resource allocation. Cancer. 2008; 113( 8 suppl): 2269–2281.
    Direct Link:
  • 15
    Fisher B,Anderson S,Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347: 1233–1241.
  • 16
    Veronesi U,Marubini E,Mariani, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001; 12: 997–1003.
  • 17
    Fyles AW,McCready DR,Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004; 351: 963–970.
  • 18
    Fisher B,Bryant J,Dignam JJ,Wickerham DL, et al; National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of 1 centimeter or less. J Clin Oncol. 2002; 20: 4141–4149.
  • 19
    Hughes KS,Schnaper LA,Berry D, et al; Cancer and Leukemia Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004; 351: 971–978.
  • 20
    Potter R,Gnant M,Kwasny W, et al; Austrian Breast and Colorectal Cancer Study Group. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 334–340.
  • 21
    Scalliet PG,Kirkove C. Breast cancer in elderly women: can radiotherapy be omitted? Eur J Cancer. 2007; 43: 2264–229.
  • 22
    Vinh-Hung V,Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004; 96: 115–121.
  • 23
    Bornstein BA,Cheng CW,Rhodes LM, et al. Can simulation measurements be used to predict the irradiated lung volume in the tangential fields in patients treated for breast cancer. Int J Radiat Oncol Biol Phys. 1990; 18: 181–187.
  • 24
    Rotstein S,Lax I,Svane G. Influence of radiation therapy on the lung-tissue in breast cancer patients: CT-assesed density changes and associated symptoms. Int J Radiat Oncol Biol Phys. 1990; 18: 173–180.
  • 25
    Borger JH,Hooning MJ,Boersma LJ, et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys. 2007; 691131–1138.
  • 26
    Kong FM,Klein EE,Bradley JD,Mansur DB, et al. The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart for intact breast radiation. Int J Radiat Oncol Biol Phys. 2002; 54: 963–971.
  • 27
    Bartelink H,Horiot JC,Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25: 3259–3265.
  • 28
    Poortmans P,Bartelink H,Horiot JC, et al; EORTC Radiotherapy and Breast Cancer Groups. The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ randomised trial. Radiother Oncol. 2004; 72: 25–33.
  • 29
    Ringash J,Whelan T,Elliott E, et al. Accuracy of ultrasound in localization of breast boost field. Radiother Oncol. 2004; 72: 61–66.
  • 30
    Jalali R,Malde R,Bhutani R,Budrukkar A,Badwe R,Sarin R. Prospective evaluation of concomitant tumour bed boost with whole breast irradiation in patients with locally advanced breast cancer undergoing breast-conserving therapy. Breast. 2008; 17: 64–70.
  • 31
    Whelan T,Pignol JP,Julian J, et al. Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node negative breast cancer [abstract]. Breast Cancer Res Treat. 2007; 106( suppl 1): s6. Abstract 21.
  • 32
    Yarnold J,Ashton A,Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005; 75: 9–17.
  • 33
    Owen JR,Ashton A,Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomized trial. Lancet Oncol. 2006; 7: 467–471.
  • 34
    Hershman DL,Wang X,McBride R,Jacobson JS,Grann VR,Neugut AI. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006; 65: 1353–1360.
  • 35
    Vujovic O,Cherian A,Yu E,Dar AR,Stitt L,Perera F. The effect of timing of radiotherapy after breast-conserving surgery in patients with positive or close resection margins, young age, and node-negative disease, with long term follow-up. Int J Radiat Oncol Biol Phys. 2006; 66: 687–690.
  • 36
    Bellon JR,Harris JR. Chemotherapy and radiation therapy for breast cancer: what is the optimal sequence? J Clin Oncol. 2005; 23: 5–7.
  • 37
    Arcangeli G,Pinnaro P,Rambone R,Giannarelli D,Benassi M. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2006; 64: 161–167.
  • 38
    Toledano A,Azria D,Garaud P, et al. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol. 2007; 25: 405–410.
  • 39
    Toledano A,Garaud P,Serin D, et al. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys. 2006; 65: 324–332.
  • 40
    Rouesse J,de la Lande B,Bertheault-Cvitkovic F, et al; Centre Rene Huguenin Breast Cancer Group. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys. 2006; 64: 1072–1080.
  • 41
    Kumpulainen EJ,Hirvikoski PP,Johansson RT. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer. Acta Oncol. 2008; 47: 120–123.
  • 42
    National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Mongr. 2001; 30: 5–15.
  • 43
    Burstein HJ,Bellon JR,Galper S, et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006; 64: 496–504.
  • 44
    Pierce LJ,Hutchins LF,Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005; 23: 24–29.
  • 45
    Ahn PH,Vu HT,Lannin D, et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol. 2005; 23: 17–23.
  • 46
    Harris EE,Christensen VJ,Hwang WT,Fox K,Solin LJ. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol. 2005; 23: 11–16.
  • 47
    Azria D,Gourgou S,Sozzi WJ, et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer. 2004; 91: 1251–1260.
  • 48
    Koc M,Polat P,Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol. 2002; 64: 171–175.
  • 49
    Vicini FA,Beitsch PD,Quiet CA, et al. First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer. 2005; 104: 1138–1148.
    Direct Link:
  • 50
    Arthur DW,Vicini FA,Kuske RR,Wazer DE,Nag S; American Brachytherapy Society. Accelerated partial breast irradiation: an updated report from the American Brachytherapy. Brachytherapy. 2003; 2: 124–130.
  • 51
    MacDonald SM,Taghian AG. Partial-breast irradiation: towards a replacement for whole breast irradiation? Expert Rev Anticancer Ther. 2007; 7: 123–134,
  • 52
    Suh WW,Pierce LJ,Vicini FA, et al. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int J Radiat Oncol Bio Phys. 2005; 62: 790–796.
  • 53
    Truong P,Woodward WA,Thames HD,Ragaz J,Olivottoo IA,Bucholz TA. The ratio of positive to excised nodes identifies high risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1–3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2007; 68: 59–65.
  • 54
    Taghian A,Jeong JH,Manounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from 5 National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004; 22: 4247–4254.
  • 55
    Chang DT,Feigenberg SJ,Indelicato DJ, et al. Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: the importance of radiation field selection. Int J Radiat Oncol Biol Phys. 2007; 67: 1043–1051.
  • 56
    Musat E,Poortmans P,Van den Bogaert W, et al. Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. Eur J Cancer. 2007; 43: 718–724.
  • 57
    Taghian AG,Jeong JH,Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from 5 National Surgical Adjuvant Breast and Powel Project randomized clinical trials. J Clin Oncol. 2006; 24: 3927–3932.
  • 58
    Aksu G,Kucucuk S,Fayda M, et al. The role of postoperative radiotherapy in node negative breast cancer patients with pT3–T4 disease. Eur J Surg Oncol. 2007; 33: 285–293.
  • 59
    Truong PT,Olivotto IA,Speers CH,Wai ES,Berthelet E,Kader HA. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 797–804.
  • 60
    Jagsi R,Raad RA,Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005; 62: 1035–1039.
  • 61
    Truong PT,Lesperance M,Culhaci A,Kader HA,Speers CH,Olivotto IA. Patient subsets with T1–T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys. 2005; 62: 175–182.
  • 62
    Rustogi A,Budrukkar A,Dinshaw K,Jalali R. Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther. 2005; 1: 21–30.
  • 63
    Bear HD,Anderson S,Brown A, et al. The effect on tumor response of adding preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol. 2003; 21: 4165–4174.
  • 64
    El Saghir NS,Eniu A,Carlson RW, et al. Management of locally advanced breast cancer: balancing clinical progress and resources. Cancer. 2008;113( 8 suppl): 2315–2324.
    Direct Link:
  • 65
    McGuire SE,Gonzalez-Angulo AM,Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007; 68: 1004–1009.
  • 66
    Kaasa S,Brenne E,Lund JA, et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy × 1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases. Radiother Oncol. 2006; 79: 278–284.
  • 67
    Salazar OM,Sandhu T,da Motta NW, et al. Fractionated half-body irradiation for the rapid palliation of widespread, symptomatic, metastatic bone diseases: a randomized phase III trial of the IAEA. Int J Radiat Oncol Biol Phys. 2001; 50: 765–775.
  • 68
    Sarin R,Budrukkar A. Efficacy, toxicity and cost-effectiveness of single-dose versus fractionated hemibody irradiation [letter]. Int J Radiat Oncol Biol Phys. 2002; 52: 1146.
  • 69
    Patchell RA,Tibbs PA,Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998; 280: 1485–1489.
  • 70
    Purdy JA,Vijayakumar S,Perez CA,Levitt SH. Physics of treatment planning in radiation oncology. In: LevittSH,PurdyJA,PerezCA,VijayakumarS, eds. Technical Basis of Radiation Therapy-Practical Clinical Applications,4th Revised Ed. New York, NY: Springer; 2006: 69–106.
  • 71
    Mutic S,Dempsey JF,Bosch WR, et al. Multimodality image registration quality assurance for conformal 3-dimensional treatment planning. Int J Radiat Oncol Biol Phys. 2001; 51: 244–260.
View Full Article (HTML) Get PDF (123K)